JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Antoch, G.
Right arrow Articles by Debatin, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Antoch, G.
Right arrow Articles by Debatin, J. F.
Journal of Nuclear Medicine Vol. 45 No. 1 (Suppl) 56S-65S
© 2004 by Society of Nuclear Medicine

To Enhance or Not to Enhance? 18F-FDG and CT Contrast Agents in Dual-Modality 18F-FDG PET/CT

Gerald Antoch, MD1, Lutz S. Freudenberg, MD2, Thomas Beyer, PhD1,2, Andreas Bockisch, MD, PhD2 and Jörg F. Debatin, MD, MBA1

1 Department of Diagnostic and Interventional Radiology, University Hospital Essen, Essen, Germany
2 Department of Nuclear Medicine, University Hospital Essen, Essen, Germany

In combined PET/CT imaging, functional data provided by 18F-FDG increase diagnostic accuracy over conventional PET and CT in a variety of malignancies. The question to be raised is: how much is CT needed in PET/CT imaging? Discussion: In stand-alone CT imaging, contrast agents are applied to aid differentiation of anatomic structures, improve lesion localization, and support lesion characterization. Based on our experience, the most important benefit when applying CT contrast agents in PET/CT imaging relates to more precise anatomic localization of pathology by differentiation of the lesion from its surrounding structures on CT. This benefit must be considered most profound in the head and neck as well as the abdomen and pelvis, where delineation of pathology from muscles, vascular structures, or the intestine is critical. CT contrast agents can be of additional value in tumors with only mild or no increase in 18F-FDG uptake by supporting lesion detection and characterization. The complementary role of CT contrast agents and molecular contrast for PET/CT imaging is addressed in this review. The authors provide specific indications as to which contrast-enhanced CT data provide additional diagnostic value. Conclusion: Functional contrast aids lesion detection and characterization, whereas morphologic contrast improves lesion localization. CT contrast agents and PET tracers do not compete but rather are complementary in combined PET/CT imaging.

Key Words: oncology • PET/CT • 18F-FDG • contrast agents • fusion




This article has been cited by other articles:


Home page
The OncologistHome page
D. Delbeke, S. Stroobants, E. de Kerviler, C. Gisselbrecht, M. Meignan, and P. S. Conti
Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma
Oncologist, October 1, 2009; 14(suppl_2): 30 - 40.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
H. J. Otero, J. T. Yap, M. A. Patak, S. M. Erturk, D. A. Israel, C. J. Johnston, C. Sakellis, F. J. Rybicki, A. D. Van den Abbeele, and P. R. Ros
Evaluation of Low-Density Neutral Oral Contrast Material in PET/CT for Tumor Imaging: Results of a Randomized Clinical Trial
Am. J. Roentgenol., August 1, 2009; 193(2): 326 - 332.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
W. De Wever, S. Stroobants, J. Coolen, and J. A. Verschakelen
Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration
Eur. Respir. J., January 1, 2009; 33(1): 201 - 212.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
D. W. Townsend
Dual-Modality Imaging: Combining Anatomy and Function
J. Nucl. Med., June 1, 2008; 49(6): 938 - 955.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
F. M. Vogt, G. Antoch, P. Veit, L. S. Freudenberg, N. Blechschmid, O. Diersch, A. Bockisch, J. Barkhausen, and H. Kuehl
Morphologic and Functional Changes in Nontumorous Liver Tissue After Radiofrequency Ablation in an In Vivo Model: Comparison of 18F-FDG PET/CT, MRI, Ultrasound, and CT
J. Nucl. Med., November 1, 2007; 48(11): 1836 - 1844.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Radiol.Home page
A C Pfannenberg, P Aschoff, K Brechtel, M Muller, M Klein, R Bares, C D Claussen, and S M Eschmann
Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging
Br. J. Radiol., June 1, 2007; 80(954): 437 - 445.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
W. De Wever, Y. Vankan, S. Stroobants, and J. Verschakelen
Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer
Eur. Respir. J., May 1, 2007; 29(5): 995 - 1002.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
T. Z. Wong, E. K. Paulson, R. C. Nelson, E. F. Patz Jr., and R. E. Coleman
Practical Approach to Diagnostic CT Combined with PET
Am. J. Roentgenol., March 1, 2007; 188(3): 622 - 629.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. E. Juweid, S. Stroobants, O. S. Hoekstra, F. M. Mottaghy, M. Dietlein, A. Guermazi, G. A. Wiseman, L. Kostakoglu, K. Scheidhauer, A. Buck, et al.
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
J. Clin. Oncol., February 10, 2007; 25(5): 571 - 578.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend
PET/CT: Form and Function
Radiology, February 1, 2007; 242(2): 360 - 385.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
J. Czernin and H. R. Schelbert
Introduction
J. Nucl. Med., January 1, 2007; 48(1_suppl): 2S - 3S.
[Full Text] [PDF]


Home page
JNMHome page
H. Kuehl, P. Veit, S. J. Rosenbaum, A. Bockisch, and G. Antoch
Can PET/CT Replace Separate Diagnostic CT for Cancer Imaging? Optimizing CT Protocols for Imaging Cancers of the Chest and Abdomen
J. Nucl. Med., January 1, 2007; 48(1_suppl): 45S - 57S.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
B. Rodriguez-Vigil, N. Gomez-Leon, I. Pinilla, D. Hernandez-Maraver, J. Coya, L. Martin-Curto, and R. Madero
PET/CT in Lymphoma: Prospective Study of Enhanced Full-Dose PET/CT Versus Unenhanced Low-Dose PET/CT
J. Nucl. Med., October 1, 2006; 47(10): 1643 - 1648.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
M. A. Blake, A. Singh, B. N. Setty, J. Slattery, M. Kalra, M. M. Maher, D. V. Sahani, A. J. Fischman, and P. R. Mueller
Pearls and Pitfalls in Interpretation of Abdominal and Pelvic PET-CT
RadioGraphics, September 1, 2006; 26(5): 1335 - 1353.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K. Brechtel, M. Klein, M. Vogel, M. Mueller, P. Aschoff, T. Beyer, S. M. Eschmann, R. Bares, C. D. Claussen, and A. C. Pfannenberg
Optimized Contrast-Enhanced CT Protocols for Diagnostic Whole-Body 18F-FDG PET/CT: Technical Aspects of Single-Phase Versus Multiphase CT Imaging
J. Nucl. Med., March 1, 2006; 47(3): 470 - 476.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. Allen-Auerbach, K. Yeom, J. Park, M. Phelps, and J. Czernin
Standard PET/CT of the Chest During Shallow Breathing Is Inadequate for Comprehensive Staging of Lung Cancer
J. Nucl. Med., February 1, 2006; 47(2): 298 - 301.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
O. Mawlawi, J. J. Erasmus, R. F. Munden, T. Pan, A. E. Knight, H. A. Macapinlac, D. A. Podoloff, and M. Chasen
Quantifying the Effect of IV Contrast Media on Integrated PET/CT: Clinical Evaluation
Am. J. Roentgenol., February 1, 2006; 186(2): 308 - 319.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
P. Raanani, Y. Shasha, C. Perry, U. Metser, E. Naparstek, S. Apter, A. Nagler, A. Polliack, I. Ben-Bassat, and E. Even-Sapir
Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?
Ann. Onc., January 1, 2006; 17(1): 117 - 122.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2004 by the Society of Nuclear Medicine.